BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reigner B, Blesch K, Weidekamm E. Clinical Pharmacokinetics of Capecitabine: . Clinical Pharmacokinetics 2001;40:85-104. [DOI: 10.2165/00003088-200140020-00002] [Cited by in Crossref: 226] [Cited by in F6Publishing: 205] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Deenen MJ, Rosing H, Hillebrand MJ, Schellens JH, Beijnen JH. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013;913-914:30-40. [PMID: 23270936 DOI: 10.1016/j.jchromb.2012.11.033] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
2 Maroun JA. Capecitabine in the management of colorectal cancer. Expert Rev Anticancer Ther 2001;1:327-33. [PMID: 12113099 DOI: 10.1586/14737140.1.3.327] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Gardiner SJ, Begg EJ, Robinson BA. The Effect of Dihydropyrimidine Dehydrogenase Deficiency on Outcomes with Fluorouracil. Adv Drug React Toxicol Rev 2002;21:1-16. [DOI: 10.1007/bf03256180] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Qvortrup C, Jensen B, Fokstuen T, Nielsen S, Keldsen N, Glimelius B, Bjerregaard B, Mejer J, Larsen F, Pfeiffer P. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer. Annals of Oncology 2010;21:87-91. [DOI: 10.1093/annonc/mdp272] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
5 Czejka M, Schueller J, Farkouh A, Gruenberger B, Scheithauer W. Plasma disposition of capecitabine and its metabolites 5′DFCR and 5′DFUR in a standard and dose-intensified monotherapy regimen. Cancer Chemother Pharmacol 2011;67:613-9. [DOI: 10.1007/s00280-010-1363-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-68. [DOI: 10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a] [Cited by in Crossref: 304] [Cited by in F6Publishing: 62] [Article Influence: 14.5] [Reference Citation Analysis]
7 Ghadiri M, Vasheghani-Farahani E, Atyabi F, Kobarfard F, Mohamadyar-Toupkanlou F, Hosseinkhani H. Transferrin-conjugated magnetic dextran-spermine nanoparticles for targeted drug transport across blood-brain barrier. J Biomed Mater Res A 2017;105:2851-64. [PMID: 28639394 DOI: 10.1002/jbm.a.36145] [Cited by in Crossref: 63] [Cited by in F6Publishing: 41] [Article Influence: 12.6] [Reference Citation Analysis]
8 Dhillon S, Scott LJ. Capecitabine: in advanced gastric or oesophagogastric cancer. Drugs. 2007;67:601-610. [PMID: 17352519 DOI: 10.2165/00003495-200767040-00010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
9 Menon A, Abraham AG, Mahfouz M, Thachuthara JJ, Usmani N, Warkentin H, Ghosh S, Nijjar T, Severin D, Tankel K, Paulson K, Mulder K, Roa W, Joseph K. Concomitant Use of Proton Pump Inhibitors With Capecitabine Based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: Is it Safe? Am J Clin Oncol 2021;44:487-94. [PMID: 34269694 DOI: 10.1097/COC.0000000000000850] [Reference Citation Analysis]
10 [DOI: 10.1101/538215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38:349-358. [PMID: 11818199 DOI: 10.1016/s0959-8049(01)00371-9] [Cited by in Crossref: 253] [Cited by in F6Publishing: 72] [Article Influence: 12.7] [Reference Citation Analysis]
12 Chu QS, Schwartz G, de Bono J, Smith DA, Koch KM, Versola MJ, Pandite L, Arya N, Curtright J, Fleming RA, Ho PT, Rowinsky EK. Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies. JCO 2007;25:3753-8. [DOI: 10.1200/jco.2007.11.1765] [Cited by in Crossref: 49] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
13 Kim YJ, Kim JH, Yu CS, Kim TW, Jang SJ, Choi EK, Kim JC, Choi W. Effect of time interval between capecitabine intake and radiotherapy on local recurrence-free survival in preoperative chemoradiation for locally advanced rectal cancer. Radiat Oncol J 2017;35:129-36. [PMID: 28712273 DOI: 10.3857/roj.2017.00010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Wagner AD, Wedding U. Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging. 2009;26:627-646. [PMID: 19685930 DOI: 10.2165/11315740-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kilburn LB, Kocak M, Baxter P, Poussaint TY, Paulino AC, McIntyre C, Lemenuel-Diot A, Lopez-Diaz C, Kun L, Chintagumpala M, Su JM, Broniscer A, Baker JN, Hwang EI, Fouladi M, Boyett JM, Blaney SM. A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer 2018;65. [PMID: 29090526 DOI: 10.1002/pbc.26832] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Invest New Drugs 2012;30:1557-65. [PMID: 21809026 DOI: 10.1007/s10637-011-9723-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
17 Carrato A, Gallego-plazas J, Guillén-ponce C. Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Expert Review of Anticancer Therapy 2014;8:161-74. [DOI: 10.1586/14737140.8.2.161] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
18 Schmiedt C, Penzo C, Schwab M, Dubielzig R, Mcanulty J. Use of Capecitabine After Renal Allograft Transplantation in Dog Erythrocyte Antigen-Matched Dogs. Veterinary Surgery 2006;35:113-24. [DOI: 10.1111/j.1532-950x.2006.00122.x] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
19 Popa EC, Shah MA. Capecitabine in the treatment of esophageal and gastric cancers. Expert Opinion on Investigational Drugs 2013;22:1645-57. [DOI: 10.1517/13543784.2013.842974] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
20 Kilburn LB, Kocak M, Schaedeli Stark F, Meneses-Lorente G, Brownstein C, Hussain S, Chintagumpala M, Thompson PA, Gururangan S, Banerjee A, Paulino AC, Kun L, Boyett JM, Blaney SM. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. Neuro Oncol 2013;15:759-66. [PMID: 23592571 DOI: 10.1093/neuonc/nos315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
21 Yamazaki K, Matsumoto S, Imamura CK, Yamagiwa C, Shimizu A, Yoshino T. Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study. Jpn J Clin Oncol 2020;50:122-8. [PMID: 31665356 DOI: 10.1093/jjco/hyz149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Molenaar-Kuijsten L, Jacobs BAW, Kurk SA, May AM, Dorlo TPC, Beijnen JH, Steeghs N, Huitema ADR. Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. Cancer Med 2021;10:4781-9. [PMID: 34121365 DOI: 10.1002/cam4.4038] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Zhang M, Wei W, Liu J, Yang H, Jiang Y, Tang W, Li Q, Liao X. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. Onco Targets Ther 2016;9:3443-50. [PMID: 27354816 DOI: 10.2147/OTT.S104431] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Saletti P, Cavalli F. Metastatic colorectal cancer. Cancer Treat Rev 2006;32:557-71. [PMID: 16935430 DOI: 10.1016/j.ctrv.2006.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
25 Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine. Cancer Chemother Pharmacol 2016;77:1201-7. [PMID: 27103124 DOI: 10.1007/s00280-016-3035-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Timmers L, Boons CC, Mangnus D, Van de Ven PM, Van den Berg PH, Beeker A, Swart EL, Honeywell RJ, Peters GJ, Boven E, Hugtenburg JG. Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. Front Pharmacol 2016;7:310. [PMID: 27708578 DOI: 10.3389/fphar.2016.00310] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
27 Villalón G, Martín JM, Pinazo MI, Calduch L, Alonso V, Jordá E. Focal Acral Hyperpigmentation in a Patient Undergoing Chemotherapy with Capecitabine: . American Journal of Clinical Dermatology 2009;10:261-3. [DOI: 10.2165/00128071-200910040-00006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
28 Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S, van Werkhoven E, Schipper L, Hoes L, Vis DJ, van de Haar J, Prevoo W, Snaebjornsson P, van der Velden D, Klein M, Chalabi M, Boot H, van Leerdam M, Bloemendal HJ, Beerepoot LV, Wessels L, Cuppen E, Clevers H, Voest EE. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med. 2019;11. [PMID: 31597751 DOI: 10.1126/scitranslmed.aay2574] [Cited by in Crossref: 134] [Cited by in F6Publishing: 131] [Article Influence: 67.0] [Reference Citation Analysis]
29 Yuan F, Zhang R, Ma X, Yang J, Huang Y, Liu Z. Cooperation effect of 4-vinylbenzeneboronic acid/methacrylic acid on affinity of capecitabine imprinted polymer for drug carrier. European Journal of Pharmaceutical Sciences 2020;154:105476. [DOI: 10.1016/j.ejps.2020.105476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs. 2008;19:447-464. [PMID: 18418212 DOI: 10.1097/cad.0b013e3282f945aa] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
31 Brems-Eskildsen AS, Linnet S, Danø H, Luczak A, Vestlev PM, Jakobsen EH, Neimann J, Jensen CB, Dongsgaard T, Langkjer ST. Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer. Acta Oncol 2021;60:157-64. [PMID: 33259244 DOI: 10.1080/0284186X.2020.1851045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Eskandari MR, Moghaddam F, Shahraki J, Pourahmad J. A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine. Xenobiotica. 2015;45:79-87. [PMID: 25034007 DOI: 10.3109/00498254.2014.942809] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
33 O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009;15:4806-4814. [PMID: 19622575 DOI: 10.1158/1078-0432.ccr-09-0344] [Cited by in Crossref: 134] [Cited by in F6Publishing: 87] [Article Influence: 10.3] [Reference Citation Analysis]
34 Lashkov AA, Zhukhlistova NE, Seregina TA, Gabdulkhakov AG, Mikhailov AM. Uridine phosphorylase in biomedical, structural, and functional aspects: A review. Crystallogr Rep 2011;56:560-89. [DOI: 10.1134/s1063774511040122] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
35 Seidman AD, de Stanchina E, Norton L, Morikawa A. Comparative Effectiveness Research Needs to Consider Optimal Dosing and Scheduling. J Clin Oncol 2021;39:253-4. [PMID: 33332193 DOI: 10.1200/JCO.20.02355] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Johnson AC, Oldenkamp R, Dumont E, Sumpter JP. Predicting concentrations of the cytostatic drugs cyclophosphamide, carboplatin, 5-fluorouracil, and capecitabine throughout the sewage effluents and surface waters of europe: Cytostatic drug concentrations in European rivers. Environ Toxicol Chem 2013;32:1954-61. [DOI: 10.1002/etc.2311] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
37 Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42:1213-42. [PMID: 14606930 DOI: 10.2165/00003088-200342140-00003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
38 Zhang S, Wang Z, Fan S, Liu T, Yoshida S, Yang S, Liu L, Hou W, Cao L, Wang J, Song Z, Li S, Zhang S, Wang H, Li J, Zheng H, Shen Z. Capecitabine Can Induce T Cell Apoptosis: A Potential Immunosuppressive Agent With Anti-Cancer Effect. Front Immunol 2021;12:737849. [PMID: 34557199 DOI: 10.3389/fimmu.2021.737849] [Reference Citation Analysis]
39 Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist. 2002;7:288-323. [PMID: 12185293 DOI: 10.1634/theoncologist.7-4-288] [Cited by in Crossref: 251] [Cited by in F6Publishing: 223] [Article Influence: 12.6] [Reference Citation Analysis]
40 Guichard SM, Macpherson JS, Mayer I, Reid E, Muir M, Dodds M, Alexander S, Jodrell DI. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. European Journal of Cancer 2008;44:310-7. [DOI: 10.1016/j.ejca.2007.10.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
41 Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. Cancer Treat Rev 2016;50:247-63. [PMID: 27776286 DOI: 10.1016/j.ctrv.2016.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
42 Lee KW, Park SR, Oh DY, Park YI, Khosravan R, Lin X, Lee SY, Roh EJ, Valota O, Lechuga MJ. Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. Invest New Drugs. 2013;31:1547-1558. [PMID: 24091982 DOI: 10.1007/s10637-013-0032-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
43 Radovanovic M, Schneider JJ, Shafiei M, Martin JH, Galettis P. Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2021;1188:123075. [PMID: 34891049 DOI: 10.1016/j.jchromb.2021.123075] [Reference Citation Analysis]
44 Kim TY, Oh DY, Bang YJ. Capecitabine for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol 2015;9:1471-81. [PMID: 26470733 DOI: 10.1586/17474124.2015.1096774] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
45 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
46 Milano G, Etienne-Grimaldi MC, Mari M, Lassalle S, Formento JL, Francoual M, Lacour JP, Hofman P. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol. 2008;66:88-95. [PMID: 18341672 DOI: 10.1111/j.1365-2125.2008.03159.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
47 Bang Y. Capecitabine in gastric cancer. Expert Review of Anticancer Therapy 2014;11:1791-806. [DOI: 10.1586/era.11.172] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
48 Hénin E, You B, Vancutsem E, Hoff P, Cassidy J, Twelves C, Zuideveld K, Sirzen F, Dartois C, Freyer G, Tod M, Girard P. A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving Capecitabine. Clin Pharmacol Ther 2008;85:418-25. [DOI: 10.1038/clpt.2008.220] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
49 Gerbrecht B. Current Canadian Experience With Capecitabine: Partnering With Patients to Optimize Therapy. Cancer Nursing 2003;26:161-7. [DOI: 10.1097/00002820-200304000-00011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
50 Upadhyay M, Adena SKR, Vardhan H, Yadav SK, Mishra B. Development of biopolymers based interpenetrating polymeric network of capecitabine: A drug delivery vehicle to extend the release of the model drug. International Journal of Biological Macromolecules 2018;115:907-19. [DOI: 10.1016/j.ijbiomac.2018.04.123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
51 Lonardi S, Bortolami A, Stefani M, Monfardini S. Oral Anticancer Drugs in the Elderly: An Overview. Drugs & Aging 2007;24:395-410. [DOI: 10.2165/00002512-200724050-00004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
52 Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs II: the prodrug strategy. Drug Discovery Today 2013;18:93-8. [DOI: 10.1016/j.drudis.2012.08.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
53 Chachad S, Purandare S, Malhotra G, Naidu R. Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. Cancer Chemother Pharmacol 2013;71:287-92. [DOI: 10.1007/s00280-012-2007-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Wang Z, Li X, Yang Y, Zhang F, Li M, Chen W, Gao S, Chen W. A Sensitive and Efficient Method for Determination of Capecitabine and Its Five Metabolites in Human Plasma Based on One-Step Liquid-Liquid Extraction. J Anal Methods Chem 2019;2019:9371790. [PMID: 30719375 DOI: 10.1155/2019/9371790] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Anticancer Drugs. 2009;20:217-229. [PMID: 19247178 DOI: 10.1097/cad.0b013e3283293fd4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
56 Saif MW. Targeting cancers in the gastrointestinal tract: role of capecitabine. Onco Targets Ther 2009;2:29-41. [PMID: 20616892 DOI: 10.2147/ott.s3469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
57 Wang F, Wang FH, Bai L, Xu RH. Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. Onco Targets Ther 2014;7:501-11. [PMID: 24729715 DOI: 10.2147/OTT.S38843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
58 Laheru D, Croghan G, Bukowski R, Rudek M, Messersmith W, Erlichman C, Pelley R, Jimeno A, Donehower R, Boni J, Abbas R, Martins P, Zacharchuk C, Hidalgo M. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin Cancer Res 2008;14:5602-9. [PMID: 18765554 DOI: 10.1158/1078-0432.CCR-08-0433] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
59 Lampropoulou DI, Laschos K, Amylidi AL, Angelaki A, Soupos N, Boumpoucheropoulos S, Papadopoulou E, Nanou E, Zidianakis V, Nasioulas G, Fildissis G, Aravantinos G. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA? J Oncol Pharm Pract. 2020;26:747-753. [PMID: 31382864 DOI: 10.1177/1078155219865597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
60 Aarnoutse R, Ziemons J, de Vos-Geelen J, Valkenburg-van Iersel L, Wildeboer ACL, Vievermans A, Creemers GM, Baars A, Vestjens HJHMJ, Le GN, Barnett DJM, Rensen SS, Penders J, Smidt ML. The Role of Intestinal Microbiota in Metastatic Colorectal Cancer Patients Treated With Capecitabine. Clin Colorectal Cancer 2021:S1533-0028(21)00102-X. [PMID: 34801414 DOI: 10.1016/j.clcc.2021.10.004] [Reference Citation Analysis]
61 Zufı́a L, Aldaz A, Giráldez J. Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection. Journal of Chromatography B 2004;809:51-8. [DOI: 10.1016/j.jchromb.2004.06.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
62 Urien S, Rezaí K, Lokiec F. Pharmacokinetic Modelling of 5-FU Production from Capecitabine—A Population Study in 40 Adult Patients with Metastatic Cancer. J Pharmacokinet Pharmacodyn 2005;32:817-33. [DOI: 10.1007/s10928-005-0018-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
63 Deng P, Ji C, Dai X, Zhong D, Ding L, Chen X. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2015;989:71-9. [PMID: 25808944 DOI: 10.1016/j.jchromb.2015.03.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
64 Cao S, Durrani FA, Rustum YM. Synergistic antitumor activity of capecitabine in combination with irinotecan. Clin Colorectal Cancer 2005;4:336-43. [PMID: 15663838 DOI: 10.3816/ccc.2005.n.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
65 Akgun Z, Saglam S, Yucel S, Gural Z, Balik E, Cipe G, Yildiz S, Kilickap S, Okyar A, Kaytan-Saglam E. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study. Cancer Chemother Pharmacol 2014;74:751-6. [PMID: 25102935 DOI: 10.1007/s00280-014-2558-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
66 Derissen EJ, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. J Pharm Biomed Anal 2015;110:58-66. [PMID: 25804433 DOI: 10.1016/j.jpba.2015.02.051] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
67 Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol 2019;42:184-9. [PMID: 30418178 DOI: 10.1097/COC.0000000000000492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
68 Gieschke R, Burger HU, Reigner B, Blesch KS, Steimer JL. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 2003;55:252-63. [PMID: 12630975 DOI: 10.1046/j.1365-2125.2003.01765.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
69 Sun J, Ilich AI, Kim CA, Chu MP, Wong GG, Ghosh S, Danilak M, Mulder KE, Spratlin JL, Chambers CR, Sawyer MB. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients. Clin Colorectal Cancer 2016;15:257-63. [PMID: 26803708 DOI: 10.1016/j.clcc.2015.12.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
70 Timmers L, Swart EL, Boons CC, Mangnus D, van de Ven PM, Peters GJ, Boven E, Hugtenburg JG. The use of capecitabine in daily practice: a study on adherence and patients' experiences. Patient Prefer Adherence 2012;6:741-8. [PMID: 23118530 DOI: 10.2147/PPA.S36757] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
71 Tsume Y, Provoda CJ, Amidon GL. The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:915-20. [PMID: 21450537 DOI: 10.1016/j.jchromb.2011.02.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
72 Belair DG, Visconti RJ, Hong M, Marella M, Peters MF, Scott CW, Kolaja KL. Human ileal organoid model recapitulates clinical incidence of diarrhea associated with small molecule drugs. Toxicol In Vitro 2020;68:104928. [PMID: 32622998 DOI: 10.1016/j.tiv.2020.104928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar HJ, Henricks LM. Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options? Clin Pharmacol Ther 2021;109:591-604. [PMID: 33020924 DOI: 10.1002/cpt.2069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
74 Derissen EJ, Jacobs BA, Huitema AD, Rosing H, Schellens JH, Beijnen JH. Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. Br J Clin Pharmacol 2016;81:949-57. [PMID: 26718616 DOI: 10.1111/bcp.12877] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
75 Dai G, Pfister M, Blackwood-Chirchir A, Roy A. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J Clin Pharmacol 2008;48:1254-69. [PMID: 18779376 DOI: 10.1177/0091270008320604] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
76 Malet-martino M, Gilard V, Desmoulin F, Martino R. Fluorine nuclear magnetic resonance spectroscopy of human biofluids in the field of metabolic studies of anticancer and antifungal fluoropyrimidine drugs. Clinica Chimica Acta 2006;366:61-73. [DOI: 10.1016/j.cca.2005.10.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
77 Quidde J, Arnold D, Stein A. Clinical management of localized colon cancer with capecitabine. Clin Med Insights Oncol 2012;6:363-73. [PMID: 23170068 DOI: 10.4137/CMO.S8194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
78 Santini D, Vincenzi B, Schiavon G, Di Seri M, Virzí V, Spalletta B, Caricato M, Coppola R, Tonini G. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemother Pharmacol 2007;59:613-20. [DOI: 10.1007/s00280-006-0302-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
79 Ackland SP, Clarke SJ, Beale P, Peters GJ. Thymidylate synthase inhibitors. Update on Cancer Therapeutics 2006;1:403-27. [DOI: 10.1016/j.uct.2006.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
80 Deenen MJ, Meulendijks D, Boot H, Legdeur MJC, Beijnen JH, Schellens JHM, Cats A. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. Cancer Chemother Pharmacol 2015;76:1285-95. [DOI: 10.1007/s00280-015-2872-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
81 Faithfull S, Deery P. Implementation of capecitabine (Xeloda®) into a cancer centre: UK experience. European Journal of Oncology Nursing 2004;8:S54-62. [DOI: 10.1016/j.ejon.2004.06.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
82 Smith DB, Neoptolemos JP. Capecitabine in carcinoma of the pancreas. Expert Opin Pharmacother 2006;7:1633-9. [PMID: 16872266 DOI: 10.1517/14656566.7.12.1633] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
83 Ferron GM, Dai Y, Semiond D. Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013;71:681-92. [PMID: 23299792 DOI: 10.1007/s00280-012-2058-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
84 Uchiyama AAT, Silva PAIA, Lopes MSM, Yen CT, Ricardo ED, Mutão T, Pimenta JR, Machado LM, Shimba DS, Peixoto RD. Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. Curr Oncol 2021;28:783-99. [PMID: 33546228 DOI: 10.3390/curroncol28010076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
85 Satoh T, Omuro Y, Sasaki Y, Hamamoto Y, Boku N, Tamura T, Ohtsu A. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer. Cancer Chemother Pharmacol 2012;69:949-55. [PMID: 22116464 DOI: 10.1007/s00280-011-1783-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
86 Matsumoto N, Kubota Y, Ishida H, Sekido M, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Ikusue T, Kobayashi K, Hisamatsu A, Toshima H, Shimada K, Fujita KI. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. Cancer Chemother Pharmacol 2020;85:1119-28. [PMID: 32458030 DOI: 10.1007/s00280-020-04087-z] [Reference Citation Analysis]
87 Janney LM, Waterbury NV. Capecitabine–Warfarin Interaction. Ann Pharmacother 2005;39:1546-51. [DOI: 10.1345/aph.1g153] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Wang J, Li C, Li P. A Small Footprint and Robust Interface for Solid Phase Microextraction and Mass Spectrometry Based on Vibrating Sharp-Edge Spray Ionization. J Am Soc Mass Spectrom 2022. [PMID: 35040644 DOI: 10.1021/jasms.1c00305] [Reference Citation Analysis]
89 Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003;63:217-36. [PMID: 12515569 DOI: 10.2165/00003495-200363020-00009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
90 Garg D, Henrich S, Salo-Ahen OM, Myllykallio H, Costi MP, Wade RC. Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. J Med Chem 2010;53:6539-49. [PMID: 20527892 DOI: 10.1021/jm901869w] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
91 Santini D, Vincenzi B, Schiavon G, La Cesa A, Gasparro S, Vincenzi A, Tonini G. Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. BMC Cancer 2006;6:42. [PMID: 16504126 DOI: 10.1186/1471-2407-6-42] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
92 O'neill V, Cassidy J. Capecitabine in the treatment of colorectal cancer. Future Oncology 2005;1:183-90. [DOI: 10.1517/14796694.1.2.183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
93 Li S, Wei W, Jiang Y, Li Q, Huang Q, Yang H, Liu J. Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer. Drug Des Devel Ther 2018;12:3085-93. [PMID: 30275685 DOI: 10.2147/DDDT.S171534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
94 Cheng V, Lemos MD, Hunter N, Badry N, Lemos JD. Concomitant use of capecitabine and proton pump inhibitors – Is it safe? J Oncol Pharm Pract 2019;25:1705-11. [DOI: 10.1177/1078155219846952] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Leong S, Eckhardt SG, Chan E, Messersmith WA, Spratlin J, Camidge DR, Diab S, Khosravan R, Lin X, Chow Maneval E, Lockhart AC. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;70:65-74. [PMID: 22623210 DOI: 10.1007/s00280-012-1880-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
96 Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004;90:1190-1197. [PMID: 15026800 DOI: 10.1038/sj.bjc.6601676] [Cited by in Crossref: 275] [Cited by in F6Publishing: 234] [Article Influence: 15.3] [Reference Citation Analysis]
97 Gadiko C, Tippabhotla SK, Thota S, Battula R, Nakkawar M, Yergude S, Khan SM, Cheerla R, Betha MR, Vobalaboina V. Comparative bioavailability study of capecitabine tablets of 500 mg in metastatic breast cancer and colorectal cancer patients under fed condition. Clinical Research and Regulatory Affairs 2012;29:72-6. [DOI: 10.3109/10601333.2012.752496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
98 Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp JR, Schouten SB, Rinkes IH, van Hillegersberg R. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer. 2010;10:545. [PMID: 20937118 DOI: 10.1186/1471-2407-10-545] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
99 McKendrick J, Coutsouvelis J. Capecitabine: effective oral fluoropyrimidine chemotherapy. Expert Opin Pharmacother 2005;6:1231-9. [PMID: 15957975 DOI: 10.1517/14656566.6.7.1231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
100 Alexandre J, Kahatt C, Bertheault-Cvitkovic F, Faivre S, Shibata S, Hilgers W, Goldwasser F, Lokiec F, Raymond E, Weems G, Shah A, MacDonald JR, Cvitkovic E. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. Invest New Drugs 2007;25:453-62. [PMID: 17628744 DOI: 10.1007/s10637-007-9071-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
101 Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 2017;3:767-773. [PMID: 27737436 DOI: 10.1001/jamaoncol.2016.3358] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
102 Jacobs BAW, Deenen MJ, Joerger M, Rosing H, de Vries N, Meulendijks D, Cats A, Beijnen JH, Schellens JHM, Huitema ADR. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis. CPT Pharmacometrics Syst Pharmacol 2019;8:940-50. [PMID: 31652031 DOI: 10.1002/psp4.12474] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
103 Kuppens IELM, Breedveld P, Beijnen JH, Schellens JHM. Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application. Cancer Investigation 2009;23:443-64. [DOI: 10.1081/cnv-58823] [Cited by in Crossref: 52] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
104 Venturini M, Del Mastro L, Garrone O, Angiolini C, Merlano M, Bergaglio M, Tolino G, Lambiase A, Baldini A, Canavese G, Rosso R. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Annals of Oncology 2002;13:546-52. [DOI: 10.1093/annonc/mdf056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
105 Gontijo AVL, Pereira SL, de Lacerda Bonfante H. Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii? Curr Microbiol 2021;79:13. [PMID: 34905109 DOI: 10.1007/s00284-021-02693-5] [Reference Citation Analysis]
106 Hénin E, Tod M, Trillet-lenoir V, Rioufol C, Tranchand B, Girard P. Pharmacokinetically Based Estimation of Patient Compliance with Oral Anticancer Chemotherapies: In Silico Evaluation. Clinical Pharmacokinetics 2009;48:359-69. [DOI: 10.2165/00003088-200948060-00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
107 Desmoulin F, Gilard V, Malet-martino M, Martino R. Metabolism of Capecitabine, an Oral Fluorouracil Prodrug: 19 F NMR Studies in Animal Models and Human Urine. Drug Metab Dispos 2002;30:1221-9. [DOI: 10.1124/dmd.30.11.1221] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
108 Rosovsky RP, Kuter DJ. Catheter-Related Thrombosis in Cancer Patients: Pathophysiology, Diagnosis, and Management. Hematology/Oncology Clinics of North America 2005;19:183-202. [DOI: 10.1016/j.hoc.2004.09.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
109 Di Costanzo F, Gasperoni S, Papaldo P, Bilancia D, Manzione L, Landucci E, Mazzoni F, Cognetti F. Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL. Annals of Oncology 2006;17:79-84. [DOI: 10.1093/annonc/mdj033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
110 DI Staso F, Gattazzo I, Salimbeni BT, Lambiase A, Scuderi G, DI Staso S, Ciancaglini M. Treatment of Capecitabine Corneal Side Effects With Autologous Blood-derived Serum Eye Drops. In Vivo 2021;35:1881-4. [PMID: 33910876 DOI: 10.21873/invivo.12451] [Reference Citation Analysis]
111 Damaraju VL, Mowles D, Wilson M, Kuzma M, Cass CE, Sawyer MB. Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers. Biochem Cell Biol 2013;91:419-27. [DOI: 10.1139/bcb-2013-0041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
112 Knikman JE, Rosing H, Guchelaar H, Cats A, Beijnen JH. A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices. Biomedical Chromatography 2019;34. [DOI: 10.1002/bmc.4732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Pandey S, Swamy SMV, Gupta A, Koli A, Patel S, Maulvi F, Vyas B. Multiple response optimisation of processing and formulation parameters of pH sensitive sustained release pellets of capecitabine for targeting colon. Journal of Microencapsulation 2018;35:259-71. [DOI: 10.1080/02652048.2018.1465138] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
114 Singh Y, Singh M, Meher JG, Pawar VK, Chourasia MK. Trichotomous gastric retention of amorphous capecitabine: An attempt to overcome pharmacokinetic gap. International Journal of Pharmaceutics 2015;478:811-21. [DOI: 10.1016/j.ijpharm.2014.11.055] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
115 Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9-22. [PMID: 27569869 DOI: 10.1016/j.ctrv.2016.08.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
116 Blesch KS, Gieschke R, Tsukamoto Y, Reigner BG, Burger HU, Steimer JL. Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs 2003;21:195-223. [PMID: 12889740 DOI: 10.1023/a:1023525513696] [Cited by in Crossref: 37] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
117 Kim SY, Lee JS, Kang J, Morita S, Park YS, Sakamoto J, Muro K, Xu RH, Kim TW. Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). Oncologist 2021;26:e954-62. [PMID: 33644953 DOI: 10.1002/onco.13735] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
118 Janssen JM, Jacobs BAW, Roosendaal J, Derissen EJB, Marchetti S, Beijnen JH, Huitema ADR, Dorlo TPC. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine. AAPS J 2021;23:23. [PMID: 33417061 DOI: 10.1208/s12248-020-00533-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, Dubin F, Semiond D, Pivot X. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer 2011;47:1037-45. [PMID: 21339064 DOI: 10.1016/j.ejca.2011.01.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
120 Sottani C, Grignani E, Zaratin L, Santorelli D, Studioso E, Lonati D, Locatelli CA, Pastoris O, Negri S, Cottica D. A new, sensitive and versatile assay for quantitative determination of α-fluoro-β-alanine (AFBA) in human urine by using the reversed-phase ultrahigh performance-tandem mass spectrometry (rp-UHPLC-MS/MS) system. Toxicol Lett 2018;298:164-70. [PMID: 30315949 DOI: 10.1016/j.toxlet.2018.10.007] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
121 Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20:1529-1534. [PMID: 19474114 DOI: 10.1093/annonc/mdp047] [Cited by in Crossref: 154] [Cited by in F6Publishing: 125] [Article Influence: 11.8] [Reference Citation Analysis]
122 Francois E, Bennouna J, Chamorey E, Etienne-Grimaldi MC, Renée N, Senellart H, Michel C, Follana P, Mari V, Douillard JY, Milano G. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. Chemotherapy 2012;58:371-80. [PMID: 23235319 DOI: 10.1159/000343969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
123 Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. J Clin Oncol 2005;23:889-98. [PMID: 15681535 DOI: 10.1200/JCO.2005.01.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
124 Nagasaka T, Mishima H, Sawaki A, Shimokawa M, Inukai M, Shinozaki K, Tanioka H, Nasu J, Nishina T, Hazama S, Okajima M, Yamaguchi Y. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study. BMJ Open 2016;6:e011454. [PMID: 27256093 DOI: 10.1136/bmjopen-2016-011454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
125 Zarfoss M, Bentley E, Milovancev M, Schmiedt C, Dubielzig R, McAnulty J. Histopathologic evidence of capecitabine corneal toxicity in dogs. Vet Pathol 2007;44:700-2. [PMID: 17846245 DOI: 10.1354/vp.44-5-700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
126 Karthikeyan K, K V S, Shaji S, M Ann C S, C S M. Capecitabine induced Steven-Johnson syndrome: A rare case report. J Oncol Pharm Pract 2021;:10781552211027945. [PMID: 34162250 DOI: 10.1177/10781552211027945] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Saeki T, Kimura T, Toi M, Taguchi T. A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer 2006;13:49-57. [DOI: 10.2325/jbcs.13.49] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
128 Chen J, Wang X, Luo P, He Q. Effects of unidentified renal insufficiency on the safety and efficacy of chemotherapy for metastatic colorectal cancer patients: a prospective, observational study. Support Care Cancer 2015;23:1043-8. [DOI: 10.1007/s00520-014-2461-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
129 Schmulenson E, Krolop L, Simons S, Ringsdorf S, Ko YD, Jaehde U. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach. Cancer Chemother Pharmacol 2020;86:435-44. [PMID: 32852627 DOI: 10.1007/s00280-020-04128-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Ma WW, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol 2010;3:373-9. [PMID: 21151476 DOI: 10.1593/tlo.10196] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
131 Karimi E, Gharib B, Rostami N, Navidpour L, Afshar M. Clinical efficacy of a topical polyherbal formulation in the management of fluorouracil -associated hand-foot syndrome. Journal of Herbal Medicine 2019;17-18:100270. [DOI: 10.1016/j.hermed.2019.100270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Sternberg CN, Reichardt P, Holland M. Development of and clinical experience with capecitabine (Xeloda®) in the treatment of solid tumours. European Journal of Oncology Nursing 2004;8:S4-S15. [DOI: 10.1016/j.ejon.2004.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
133 Santini D, Virzí V, Vincenzi B, Rocci L, Leoni V, Tonini G. A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients. Ann Oncol 2007;18:576-80. [PMID: 17158771 DOI: 10.1093/annonc/mdl440] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
134 Rivera E, Chang JC, Semiglazov V, Burdaeva O, Kirby MG, Spector T. Eniluracil Plus 5-Fluorouracil and Leucovorin: Treatment for Metastatic Breast Cancer Patients in Whom Capecitabine Treatment Rapidly Failed. Clinical Breast Cancer 2014;14:26-30. [DOI: 10.1016/j.clbc.2013.08.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
135 Schott AF, Rae JM, Griffith KA, Hayes DF, Sterns V, Baker LH. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol 2006;58:129-35. [DOI: 10.1007/s00280-005-0132-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
136 Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol. 2004;15:1344-1347. [PMID: 15319239 DOI: 10.1093/annonc/mdh343] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 4.8] [Reference Citation Analysis]
137 van Doorn L, Heersche N, de Man FM, de Bruijn P, Bijl I, Oomen-de Hoop E, Eskens FALM, van der Gaast A, Mathijssen RHJ, Bins S. Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial. Clin Pharmacol Ther 2021. [PMID: 34656072 DOI: 10.1002/cpt.2444] [Reference Citation Analysis]
138 Mihaljevic A, Büchler P, Harder J, Hofheinz R, Gregor M, Kanzler S, Schmiegel W, Heinemann V, Endlicher E, Klöppel G, Seufferlein T, Geissler M. A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer. BMC Surg 2009;9:1. [PMID: 19133157 DOI: 10.1186/1471-2482-9-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
139 Prokofev II, Lashkov AA, Gabdulkhakov AG, Balaev VV, Seregina TA, Mironov AS, Betzel C, Mikhailov AM. X-ray structures of uridine phosphorylase from Vibrio cholerae in complexes with uridine, thymidine, uracil, thymine, and phosphate anion: Substrate specificity of bacterial uridine phosphorylases. Crystallogr Rep 2016;61:954-73. [DOI: 10.1134/s1063774516060134] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
140 Lee J, Kang Y. Capecitabine in the treatment of advanced gastric cancer. Future Oncology 2008;4:179-98. [DOI: 10.2217/14796694.4.2.179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
141 Glynne-jones R, Dunst J, Sebag-montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Annals of Oncology 2006;17:361-71. [DOI: 10.1093/annonc/mdj052] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 4.0] [Reference Citation Analysis]
142 Daher Abdi Z, Lavau-Denes S, Prémaud A, Urien S, Sauvage FL, Martin J, Leobon S, Marquet P, Tubiana-Mathieu N, Rousseau A. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer. Cancer Chemother Pharmacol 2014;73:1285-93. [PMID: 24801171 DOI: 10.1007/s00280-014-2466-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
143 Wagstaff AJ, Ibbotson T, Goa KL. Spotlight on Capecitabine in the Management of Advanced Breast Cancer1: . American Journal of Cancer 2003;2:137-40. [DOI: 10.2165/00024669-200302020-00008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
144 Wan L, Cao D, Zeng J, Ziemba A, Pizzorno G. Activation of Stat1, IRF-1, and NF-kappaB is required for the induction of uridine phosphorylase by tumor necrosis factor-alpha and interferon-gamma. Nucleosides Nucleotides Nucleic Acids 2010;29:488-503. [PMID: 20544543 DOI: 10.1080/15257771003729682] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
145 Kristensen M, Pedersen P, Mejer J. The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-Related Toxicity in Colorectal Cancer Patients. J Int Med Res 2010;38:1313-23. [DOI: 10.1177/147323001003800413] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
146 McLeod JR, Harvey PA, Detweiler CS. An Oral Fluorouracil Prodrug, Capecitabine, Mitigates a Gram-Positive Systemic Infection in Mice. Microbiol Spectr 2021;9:e0027521. [PMID: 34190602 DOI: 10.1128/Spectrum.00275-21] [Reference Citation Analysis]
147 Venturini M. Rational development of capecitabine. European Journal of Cancer 2002;38:3-9. [DOI: 10.1016/s0959-8049(01)00414-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
148 Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol. 2010;28:4513-4520. [PMID: 20837944 DOI: 10.1200/jco.2009.26.9696] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
149 Koizumi W, Okayasu I, Hyodo I, Sakamoto J, Kojima H. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anti-Cancer Drugs 2008;19:819-24. [DOI: 10.1097/cad.0b013e3283094b5d] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
150 Gieschke R, Reigner B, Blesch KS, Steimer JL. Population pharmacokinetic analysis of the major metabolites of capecitabine. J Pharmacokinet Pharmacodyn 2002;29:25-47. [PMID: 12194534 DOI: 10.1023/a:1015716617967] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
151 Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PLoS One 2013;8:e67330. [PMID: 23840665 DOI: 10.1371/journal.pone.0067330] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
152 Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. The Lancet Oncology 2018;19:880-8. [DOI: 10.1016/s1470-2045(18)30256-0] [Cited by in Crossref: 82] [Cited by in F6Publishing: 35] [Article Influence: 20.5] [Reference Citation Analysis]
153 Švobaitė R, Solassol I, Pinguet F, Mazard T, Ivanauskas L, Ychou M, Bressolle FMM. A LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY METHOD FOR THE SIMULTANEOUS DETERMINATION OF CAPECITABINE, 5′-DEOXY-5-FLUOROCYTIDINE, 5′-DEOXY-5-FLUOROURIDINE, 5-FLUOROURACIL, AND 5-FLUORODIHYDROURACIL IN HUMAN PLASMA. Journal of Liquid Chromatography & Related Technologies 2010;33:1705-19. [DOI: 10.1080/10826076.2010.503842] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
154 Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manag Res 2011;3:79-89. [PMID: 21629830 DOI: 10.2147/CMR.S11250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.3] [Reference Citation Analysis]
155 Shore S, Raraty MG, Ghaneh P, Neoptolemos JP. Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 2003;18:1049-69. [PMID: 14653825 DOI: 10.1111/j.1365-2036.2003.01781.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
156 Noh YJ, Choi WS, Kim JH, Kim JC, Yu CS, Kim HC, Kim TW, Chang HM, Ryu MH, Ahn SD, Lee SW, Shin SS, Lee JE, Choi EK. Optimal timing for the administration of capecitabine with preoperative chemoradiation for locally advanced rectal cancer. Cancer Res Treat 2006;38:30-4. [PMID: 19771256 DOI: 10.4143/crt.2006.38.1.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncol 2015;17:289-95. [PMID: 25015089 DOI: 10.1093/neuonc/nou141] [Cited by in Crossref: 104] [Cited by in F6Publishing: 99] [Article Influence: 13.0] [Reference Citation Analysis]
158 Daniele G, Gallo M, Piccirillo MC, Giordano P, D'Alessio A, Del Giudice A, La Porta ML, Perrone F, Normanno N, De Luca A. Pharmacokinetic evaluation of capecitabine in breast cancer. Expert Opin Drug Metab Toxicol 2013;9:225-35. [PMID: 23301520 DOI: 10.1517/17425255.2013.759939] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
159 Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther 2020;206:107447. [PMID: 31756363 DOI: 10.1016/j.pharmthera.2019.107447] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 24.3] [Reference Citation Analysis]
160 Fischel JL, Formento P, Ciccolini J, Etienne-Grimaldi MC, Milano G. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes. Anticancer Drugs 2004;15:969-74. [PMID: 15514566 DOI: 10.1097/00001813-200411000-00006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
161 Bruno R, Lindbom L, Schaedeli Stark F, Chanu P, Gilberg F, Frey N, Claret L. Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer. CPT Pharmacometrics Syst Pharmacol 2012;1:e19. [PMID: 23835839 DOI: 10.1038/psp.2012.20] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
162 Shin SJ, Ahn JB, Park KS, Lee YJ, Hong YS, Kim TW, Kim HR, Rha SY, Roh JK, Kim DH. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Invest New Drugs. 2012;30:672-680. [PMID: 21188464 DOI: 10.1007/s10637-010-9625-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
163 Pham T, Plata PL, Zhang P, Vellara A, Bu W, Lin B, Cheng G, Liu Y. Knowledge-Based Design of 5-Fluororacil Prodrug Liposomal Formulation: Molecular Packing and Interaction Revealed by Interfacial Isotherms and X-ray Scattering Techniques. Mol Pharm 2021;18:4331-40. [PMID: 34739257 DOI: 10.1021/acs.molpharmaceut.1c00494] [Reference Citation Analysis]
164 Mikhail SE, Sun JF, Marshall JL. Safety of capecitabine: a review. Expert Opinion on Drug Safety 2010;9:831-41. [DOI: 10.1517/14740338.2010.511610] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
165 Milano G, Ferrero JM, François E. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer 2004;91:613-7. [PMID: 15280932 DOI: 10.1038/sj.bjc.6601973] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
166 Bajetta E, Pietrantonio F, Buzzoni R, Ferrario E, Valvo F, Mariani L, Dotti KF, Biondani P, Formisano B, Gevorgyan A, Grassi P, Di Bartolomeo M. Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. Am J Clin Oncol 2014;37:545-9. [PMID: 23428953 DOI: 10.1097/COC.0b013e31827ecd1d] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
167 Rabinowits G, Bhupalam L, Miller DM, Kloecker GH, Laber DA. Fixed-Dose Every-Other-Week Capecitabine and Oxaliplatin for Refractory Squamous Cell Carcinoma of the Head and Neck. The American Journal of the Medical Sciences 2010;339:148-51. [DOI: 10.1097/maj.0b013e3181c4bd91] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
168 Pivot X, Chamorey E, Guardiola E, Magné N, Thyss A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G. Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 2003;14:1578-86. [PMID: 14504061 DOI: 10.1093/annonc/mdg410] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
169 Arslan C, Aksoy S, Dizdar O, Kurt M, Guler N, Ozisik Y, Gullu I, Altundag K. Increased Mean Corpuscular Volume of Erythrocytes during Capecitabine Treatment: A Simple Surrogate Marker for Clinical Response. Tumori 2011;97:711-6. [DOI: 10.1177/030089161109700606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
170 Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27:23-44. [PMID: 15763604 DOI: 10.1016/j.clinthera.2005.01.005] [Cited by in Crossref: 362] [Cited by in F6Publishing: 321] [Article Influence: 21.3] [Reference Citation Analysis]
171 Jain AK, Jain S. Advances in oral delivery of anti-cancer prodrugs. Expert Opin Drug Deliv 2016;13:1759-75. [PMID: 27292717 DOI: 10.1080/17425247.2016.1200554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
172 Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974-984. [PMID: 23582737 DOI: 10.1016/j.ctrv.2013.03.005] [Cited by in Crossref: 151] [Cited by in F6Publishing: 124] [Article Influence: 16.8] [Reference Citation Analysis]
173 Ebi H, Sigeoka Y, Saeki T, Kawada K, Igarashi T, Usubuchi N, Ueda R, Sasaki Y, Minami H. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). Cancer Chemother Pharmacol. 2005;56:205-211. [PMID: 15844007 DOI: 10.1007/s00280-004-0934-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
174 Conroy T, Hebbar M, Bennouna J, Ducreux M, Ychou M, Llédo G, Adenis A, Faroux R, Rebischung C, Kockler L. Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. Br J Cancer. 2010;102:59-67. [PMID: 19920832 DOI: 10.1038/sj.bjc.6605442] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
175 Yu CS, Kim TW, Kim JH, Choi WS, Kim HC, Chang HM, Ryu MH, Jang SJ, Ahn SD, Lee S, Shin SS, Choi EK, Kim JC. Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer. International Journal of Radiation Oncology*Biology*Physics 2007;67:1020-6. [DOI: 10.1016/j.ijrobp.2006.10.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
176 Mcgavin JK, Goa KL. Capecitabine: A Review of its Use in the Treatment of Advanced or Metastatic Colorectal Cancer. Drugs 2001;61:2309-26. [DOI: 10.2165/00003495-200161150-00015] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
177 Wang YL, Hsu LF. Evaluating the Feasibility of Use of a Foreign Reference Product for Generic Drug Applications: A Retrospective Pilot Study. Eur J Drug Metab Pharmacokinet 2017;42:935-42. [PMID: 28283987 DOI: 10.1007/s13318-017-0409-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
178 Vacondio F, Silva C, Mor M, Testa B. Qualitative structure-metabolism relationships in the hydrolysis of carbamates. Drug Metab Rev 2010;42:551-89. [PMID: 20441444 DOI: 10.3109/03602531003745960] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
179 Iqbal S, Lenz H. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. Expert Review of Anticancer Therapy 2014;4:947-55. [DOI: 10.1586/14737140.4.6.947] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
180 Santini D, Vincenzi B, La Cesa A, Caricato M, Schiavon G, Spalletta B, Di Seri M, Coppola R, Rocci L, Tonini G. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Oncology 2005;69:27-34. [PMID: 16088232 DOI: 10.1159/000087285] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
181 Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer. 2005;92:820-826. [PMID: 15756252 DOI: 10.1038/sj.bjc.6602354] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
182 Pilancı KN, Saglam S, Okyar A, Yucel S, Pala-Kara Z, Ordu C, Namal E, Ciftci R, Iner-Koksal U, Kaytan-Saglam E. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. Cancer Chemother Pharmacol 2016;78:143-50. [PMID: 27270460 DOI: 10.1007/s00280-016-3067-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
183 Zhu AX, Willett CG. Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. Semin Radiat Oncol. 2003;13:454-468. [PMID: 14586834 DOI: 10.1016/S1053-4296(03)00048-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
184 Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov 2018;17:559-87. [DOI: 10.1038/nrd.2018.46] [Cited by in Crossref: 200] [Cited by in F6Publishing: 171] [Article Influence: 50.0] [Reference Citation Analysis]
185 Baymak MS, Celik H, Ozkan SA. The Application of Differential Pulse Polarography to the Analysis of Capecitabine and Investigation of Its Electroreduction Mechanism. J Electrochem Soc 2015;162:G29-35. [DOI: 10.1149/2.0021507jes] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
186 Camidge R, Reigner B, Cassidy J, Grange S, Abt M, Weidekamm E, Jodrell D. Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Cancer. JCO 2005;23:4719-25. [DOI: 10.1200/jco.2005.09.129] [Cited by in Crossref: 54] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
187 Dhananjeyan MR, Liu J, Bykowski C, Trendel JA, Sarver JG, Ando H, Erhardt PW. Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography. Journal of Chromatography A 2007;1138:101-8. [DOI: 10.1016/j.chroma.2006.10.038] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
188 Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. Journal of Pharmaceutical Sciences 2008;97:1109-34. [DOI: 10.1002/jps.21047] [Cited by in Crossref: 110] [Cited by in F6Publishing: 97] [Article Influence: 7.9] [Reference Citation Analysis]
189 Sekido M, Fujita K, Kubota Y, Ishida H, Takahashi T, Ohkuma R, Tsunoda T, Ishikawa F, Shibanuma M, Sasaki Y. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil. Cancer Chemother Pharmacol 2019;83:1127-35. [DOI: 10.1007/s00280-019-03837-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
190 Saracoglu H, Baskol G, Baskol M. Macrolipasemia secondary to colon cancer chemotherapy: a case report. Biochem Med (Zagreb) 2021;31:030801. [PMID: 34658648 DOI: 10.11613/BM.2021.030801] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Roosendaal J, Jacobs BAW, Pluim D, Rosing H, de Vries N, van Werkhoven E, Nuijen B, Beijnen JH, Huitema ADR, Schellens JHM, Marchetti S. Phase I pharmacological study of continuous chronomodulated capecitabine treatment. Pharm Res 2020;37:89. [PMID: 32382808 DOI: 10.1007/s11095-020-02828-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
192 Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S. Possible Pathways of Capecitabine-Induced Hand–Foot Syndrome. Chem Res Toxicol 2016;29:1591-601. [DOI: 10.1021/acs.chemrestox.6b00215] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
193 Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 2006;94:964-8. [PMID: 16552436 DOI: 10.1038/sj.bjc.6603049] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
194 Marsé H, Van Cutsem E, Grothey A, Valverde S. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®). European Journal of Oncology Nursing 2004;8:S16-30. [DOI: 10.1016/j.ejon.2004.06.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
195 Pentheroudakis G, Pappas P, Golfinopoulos V, Fountzilas G, Nikolaidou M, Boumba VA, Vougiouklakis T, Nikiforidis L, Tzamakou E, Siarabi O, Marselos M, Pavlidis N. Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. Cancer Chemother Pharmacol 2007;60:733-9. [PMID: 17333194 DOI: 10.1007/s00280-007-0419-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
196 Giessen C, von Weikersthal LF, Hinke A, Stintzing S, Kullmann F, Vehling-Kaiser U, Mayerle J, Bangerter M, Denzlinger C, Sieber M. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. BMC Cancer. 2011;11:367. [PMID: 21861888 DOI: 10.1186/1471-2407-11-367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
197 Campone M, Isambert N, Bourbouloux E, Roché H, Bonneterre J, Milano G, Fumoleau P. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 2012;69:871-9. [DOI: 10.1007/s00280-011-1767-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
198 Ramírez J, House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, Ratain MJ, Sharma MR. Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. The Journal of Clinical Pharmacology 2019;59:1632-40. [DOI: 10.1002/jcph.1476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP Jr, McLeod HL, Davidson NE, Wolff AC. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat 2013;139:135-43. [PMID: 23588952 DOI: 10.1007/s10549-013-2516-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
200 Schneider JJ, Galettis P, Martin JH. Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine. Br J Clin Pharmacol 2021;87:317-25. [PMID: 33386659 DOI: 10.1111/bcp.14723] [Reference Citation Analysis]
201 Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. Int J Radiat Oncol Biol Phys. 2013;85:e201-e207. [PMID: 23517808 DOI: 10.1016/j.ijrobp.2012.12.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
202 Winer A, Denlinger CS, Vijayvergia N, Cohen SJ, Astaturov I, Dotan E, Gallant JN, Wang EW, Kunkel M, Lim B, Harvey HA, Sivik J, Korzekwa K, Ruth K, White K, Cooper HS, Ross EA, Zhou L, El-Deiry WS. First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. Clin Colorectal Cancer 2021;20:e43-52. [PMID: 32972830 DOI: 10.1016/j.clcc.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Derissen EJB, Beijnen JH. Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action. Clin Pharmacokinet 2020;59:1521-50. [PMID: 33064276 DOI: 10.1007/s40262-020-00934-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
204 Montange D, Bérard M, Demarchi M, Muret P, Piédoux S, Kantelip JP, Royer B. An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma. J Mass Spectrom 2010;45:670-7. [PMID: 20527036 DOI: 10.1002/jms.1759] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
205 Di Desidero T, Orlandi P, Fioravanti A, Cremolini C, Loupakis F, Marmorino F, Antoniotti C, Masi G, Lonardi S, Bergamo F, Zagonel V, Falcone A, Bocci G. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. Invest New Drugs 2018;36:709-14. [PMID: 29488048 DOI: 10.1007/s10637-018-0579-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
206 Cao D, Ziemba A, McCabe J, Yan R, Wan L, Kim B, Gach M, Flynn S, Pizzorno G. Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity. Mol Cancer Ther 2011;10:2330-9. [PMID: 21954436 DOI: 10.1158/1535-7163.MCT-11-0202] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
207 Iqbal H, Pan Q. Capecitabine for treating head and neck cancer. Expert Opin Investig Drugs 2016;25:851-9. [PMID: 27144283 DOI: 10.1080/13543784.2016.1181747] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
208 Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. A phase I study of an oral simulated FOLFOX with high dose capecitabine. Invest New Drugs 2009;27:461-8. [PMID: 19129971 DOI: 10.1007/s10637-008-9210-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
209 Farid M, Chowbay B, Chen X, Tan SH, Ramasamy S, Koo WH, Toh HC, Choo SP, Ong SY. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. Cancer Chemother Pharmacol 2012;70:141-50. [PMID: 22648745 DOI: 10.1007/s00280-012-1895-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
210 Saji S, Toi M, Morita S, Iwata H, Ito Y, Ohno S, Kobayashi T, Hozumi Y, Sakamoto J. Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. Oncology 2007;72:330-7. [PMID: 18187954 DOI: 10.1159/000113062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
211 Pavlak M, Stojković R, Radačić-aumiler M, Kašnar-šamprec J, Jerčić J, Vlahović K, Žinić B, Radačić M. Antitumor activity of novel N-sulfonylpyrimidine derivatives on the growth of anaplastic mammary carcinoma in vivo. J Cancer Res Clin Oncol 2005;131:829-36. [DOI: 10.1007/s00432-005-0026-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
212 Vázquez-bayo C, Rodríguez-bujaldón A, Jiménez-puya R, Galán-gutiérrez M, Moreno-giménez J. Hiperpigmentación secundaria a capecitabina. Actas Dermo-Sifiliográficas 2007;98:491-3. [DOI: 10.1016/s0001-7310(07)70114-x] [Cited by in Crossref: 11] [Article Influence: 0.7] [Reference Citation Analysis]
213 Forough M, Farhadi K, Molaei R, Khalili H, Shakeri R, Zamani A, Matin AA. Capillary electrophoresis with online stacking in combination with AgNPs@MCM-41 reinforced hollow fiber solid-liquid phase microextraction for quantitative analysis of Capecitabine and its main metabolite 5-Fluorouracil in plasma samples isolated from cancer patients. Journal of Chromatography B 2017;1040:22-37. [DOI: 10.1016/j.jchromb.2016.11.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
214 Huang Y, Yu Q, Liu Y, Zhu Z, Wang L, Wang H, Li K. Efficacy and safety of chronomodulated chemotherapy for patients with metastatic colorectal cancer: a systematic review and meta-analysis. Asia Pac J Clin Oncol 2017;13:e171-8. [PMID: 26892158 DOI: 10.1111/ajco.12456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
215 Kobuchi S, Yazaki Y, Ito Y, Sakaeda T. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. Eur J Pharm Sci 2018;112:152-8. [PMID: 29175408 DOI: 10.1016/j.ejps.2017.11.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
216 Isaacs K, Haim N. Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature. J Chemother 2005;17:339-42. [PMID: 16038530 DOI: 10.1179/joc.2005.17.3.339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]